Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | INCB099318 |
| Synonyms | |
| Therapy Description |
INCB099318 inhibits PD-L1 (CD274), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| INCB099318 | INCB-099318|INCB 099318|INCB99318|INCB 99318|INCB-99318 | Immune Checkpoint Inhibitor 150 PD-L1 Inhibitor 15 | INCB099318 inhibits PD-L1 (CD274), potentially resulting in antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04272034 | Phase I | INCB099318 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | Terminated | USA | SWE | NOR | GBR | FIN | DNK | BEL | 0 |